Company profile
Entera Bio Ltd.
NASDAQ:ENTXBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| TERIPARATIDE | phase1 | — | 32 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02152228 | phase2 | completed | 2014-07-01 | 2015-06-01 | Entera Bio Ltd. | A Pilot Study to Assess the Safety and Efficacy of Oral PTH (1-34) in the Treatment of Hypoparathyroidism |
| NCT04003467 | phase2 | completed | 2019-06-30 | 2021-04-27 | Entera Bio Ltd. | A Six-month Phase 2 Study of Oral hPTH(1-34) (EBP05) in Postmenopausal Women With Low Bone Mass |
| NCT02571140 | phase1 | completed | 2013-10-01 | 2017-08-01 | Entera Bio Ltd. | A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) Formulations in Healthy Subjects |
| NCT02202603 | phase1 | completed | 2011-07-01 | 2013-08-01 | Entera Bio Ltd. | A Three Stage, Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) in Healthy Subjects |
| NCT05965167 | phase1 | completed | 2023-05-11 | 2026-02-08 | Entera Bio Ltd. | Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo |
FDA applications (0)
No records yet.